Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| MACS-2022-120102 | Other Identifier | Study ID | |
| EXPLORER 2.0 | Other Identifier | Takeda |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The main aim of this study is to learn about the effect of treatment with vedolizumab IV (vedolizumab) together with adalimumab or vedolizumab (VDZ) together with ustekinumab (UST) in adults with moderate to severe Crohn's Disease, and the effect of treatment with vedolizumab alone, after the dual targeted treatment.
The study is conducted in two parts. In Part A, participants will receive the dual targeted treatment (vedolizumab together with either adalimumab or ustekinumab). In part B, participants will receive vedolizumab only. Part B will include participants who responded to the treatment in Part A.
Each participant will be followed up for at least 26 weeks after the last dose of treatment.
The drug being tested in this study is vedolizumab. Vedolizumab is being tested to treat people with moderate to severe Crohn's disease who have experienced inadequate response, loss of response or intolerance to either one prior interleukin [IL] antagonist, and no other biologic/small molecule (Group A); one IL antagonist and either one Janus kinase inhibitor (JAKi) or one TNFi (other than adalimumab) [Group B] (Cohort 1) or one prior tumor necrosis factor inhibitor [TNFi] and no other biologic/small molecule (Group C); one TNFi and either 1 JAKi or one IL antagonist (other than UST) (Group D) (Cohort 2). The study will look at the efficacy and safety of dual targeted therapy.
The study will enroll approximately 100 participants. Participants will be assigned to one of the two treatment groups in Part A:
All participants who achieve therapeutic benefit in Part A will receive vedolizumab IV 300 mg monotherapy from Week 30 until Week 46 in Part B. Participants will be followed for a further 20-week safety follow-up period to Week 72 (or 26 weeks post-last dose of study drug).
This multi-center trial will be conducted in the United States and Canada. The overall time to participate in this study is approximately 76 weeks.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Part A, Cohort 1: Vedolizumab + Adalimumab | Experimental | Participants will receive vedolizumab IV 300 mg, at Weeks 0, 2, and 6, then every 8 weeks (Q8W) until Week 22 and adalimumab SC 160, 80, and 40 mg at Weeks 0, 2, and 4, respectively, then 40 mg every 2 weeks (Q2W) until Week 26. |
|
| Part A, Cohort 2: Vedolizumab + Ustekinumab | Experimental | Participants will receive vedolizumab IV 300 mg, at Weeks 0, 2, and 6, then Q8W until Week 22 and ustekinumab IV 520, 390, or 260 mg (weight-based), then SC 90 mg 8 weeks after initial IV dose, then Q8W until Week 24. |
|
| Part B: Vedolizumab Monotherapy | Experimental | Participants who achieve therapeutic benefit in Part A will receive vedolizumab IV 300 mg monotherapy, Q8W from Week 30 until Week 46 and will be followed up to Week 52. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Vedolizumab | Drug | Vedolizumab intravenous infusion. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Part A: Percentage of Participants With an Endoscopic Response Based on the Simple Endoscopic Score for (SES-CD) at Week 26 | Endoscopic response is defined by a >=50 percent (%) reduction from baseline in the SES-CD. SES-CD evaluates 4 endoscopic variables (ulcer size, percentage of surface area (SA) that is ulcerated, percentage of SA affected, and presence and type of narrowings in 5 colonic segments evaluated during ileocolonoscopy. Each variable is coded from 0 to 3 based on severity, where 0 is none or not severe and 3 is most severe case, with sum of scores for each variable ranging from 0 to 15, except for presence of narrowing. Presence of narrowing ranges from 0 to 11 since a severity of 3 represents a narrowing which a colonoscope cannot be passed and, thus, can only be observed once among the bowel segments. The overall SES-CD score ranges from 0 to 56 and is the sum of 4 variables across 5 bowel segments. Higher scores indicate more severe disease. | At Week 26 |
| Part B: Percentage of Participants With an Endoscopic Response Based on the SES-CD at Week 52 | Endoscopic response is defined by a >=50 reduction from baseline in the SES-CD. SES-CD evaluates 4 endoscopic variables (ulcer size, percentage of surface area (SA) that is ulcerated, percentage of SA affected, and presence and type of narrowings in 5 colonic segments evaluated during ileocolonoscopy. Each variable is coded from 0 to 3 based on severity, where 0 is none or not severe and 3 is most severe case, with sum of scores for each variable ranging from 0 to 15, except for presence of narrowing. Presence of narrowing ranges from 0 to 11 since a severity of 3 represents a narrowing which a colonoscope cannot be passed and, thus, can only be observed once among the bowel segments. The overall SES-CD score ranges from 0 to 56 and is the sum of 4 variables across 5 bowel segments. Higher scores indicate more severe disease. | At Week 52 |
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of Participants in Clinical Remission Based on the Crohn's Disease Activity Index (CDAI) (CDAI <150) at Week 12, Week 26, and Week 52 | Clinical remission is defined as a CDAI score of <150 points. CDAI assesses CD based on clinical signs such as number of liquid or very soft stools, abdominal pain, general wellbeing, extra-intestinal manifestations of CD, antidiarrheal use, presence of abdominal mass, hematocrit and body weight. CDAI consists of eight factors, each summed after adjustment with a weighting factor. Total score ranges from 0 to 600 points. Higher scores indicate more severity. Percentage of participants in clinical remission based on CDAI at either Week 12, Week 26, or Week 52 will be reported in this outcome measure. |
Not provided
Inclusion Criteria:
Part A:
Has a confirmed diagnosis of CD at least 3 months before screening, based on endoscopy results.
Has moderately to severely active CD at Screening, defined as an SES-CD >=6 (>=4 if isolated ileal disease).
Has demonstrated at least 1 of the following (a, b, or c) to at least 1 IL antagonist or at least 1 tumor necrosis factor (TNF) antagonist, at doses approved for the treatment of CD:
Note: Participants with an inadequate response to >2 classes of advanced therapies or >1 agent in the same class are not eligible. Participants who discontinued a third class of advanced therapy for reasons other than inadequate response may be eligible after discussion with the Medical Monitor.
Part B:
In the investigator's opinion, the participant exhibits a therapeutic benefit at Week 26.
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Takeda Contact | Contact | +1-877-825-3327 | medinfoUS@takeda.com |
| Name | Affiliation | Role |
|---|---|---|
| Study Director | Takeda | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Digestive Health Specialsits | Recruiting | Dothan | Alabama | 36301 | United States |
Not provided
| Label | URL |
|---|---|
| Click here for more information about this trial in easy-to-understand language, including a Plain Language Summary of the results if the trial has been completed. | View source |
Not provided
Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
Not provided
IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Adalimumab | Drug | Adalimumab subcutaneous injection. |
|
|
| Ustekinumab | Drug | Ustekinumab intravenous infusion. |
|
|
| Ustekinumab | Drug | Ustekinumab subcutaneous injection. |
|
|
| At Weeks 12, 26, and 52 |
| Percentage of Participants in Clinical Remission at Both Week 26 and Week 52 | Clinical remission is defined as a CDAI score of ≤150 points. CDAI assesses CD based on clinical signs such as number of liquid or very soft stools, abdominal pain, general wellbeing, extra-intestinal manifestations of CD, antidiarrheal use, presence of abdominal mass, hematocrit and body weight. CDAI consists of eight factors, each summed after adjustment with a weighting factor. Total score ranges from 0 to 600 points. Higher scores indicate more severity. Percentage of participants in clinical remission at both Week 26 and Week 52 will be reported in this outcome measure. | At Weeks 26 and 52 |
| Percentage of Participants in 2-item Patient-reported Outcome Measure (PRO2) Remission at Weeks 12, 26, and 52 | Clinical remission based on PRO2 is defined as PRO2 score <=8 from baseline. The PRO2 is comprised of the stool frequency and abdominal pain components of the CDAI. The PRO-2 score is the sum of the abdominal pain and stool frequency subscores of the CDAI score. The average daily number of liquid or very soft stools and abdominal pain score (with 0 indicating no pain and 3 indicating severe pain) are weighted according to the CDAI multiplication factors (2 for stool frequency and 5 for abdominal pain). A higher score indicates more frequent stools and more severe abdominal pain. | At Weeks 12, 26 and 52 |
| Change in PRO2 Score from Week 26 to 52 | The PRO2 is comprised of the stool frequency and abdominal pain components of the CDAI. The PRO-2 score is the sum of the abdominal pain and stool frequency subscores of the CDAI score. The average daily number of liquid or very soft stools and abdominal pain score (with 0 indicating no pain and 3 indicating severe pain) are weighted according to the CDAI multiplication factors (2 for stool frequency and 5 for abdominal pain). A higher score indicates more frequent stools and more severe abdominal pain. | From Week 26 up to Week 52 |
| Percentage of Participants in Stool Frequency Remission | Stool frequency remission is defined as an average daily stool frequency of <=3 that is not worse than baseline. | At Weeks 12, 26, and 52 |
| Percentage of Participants in Abdominal Pain Remission | Abdominal pain remission is defined as an abdominal pain score of <=1 that is not worse than baseline. | At Weeks 12, 26, and 52 |
| Percentage of Participants in Endoscopic Remission (SES-CD 0-2) at Week 26 and Week 52 | Endoscopic remission is defined as SES-CD score from 0-2. SES-CD evaluates 4 endoscopic variables (ulcer size, percentage of surface area (SA) that is ulcerated, percentage of SA affected, and presence and type of narrowings in 5 colonic segments evaluated during ileocolonoscopy. Each variable is coded from 0 to 3 based on severity, where 0 is none or not severe and 3 is most severe case, with sum of scores for each variable ranging from 0 to 15, except for presence of narrowing. Presence of narrowing ranges from 0 to 11 since a severity of 3 represents a narrowing which a colonoscope cannot be passed and, thus, can only be observed once among the bowel segments. The overall SES-CD score ranges from 0 to 56 and is sum of 4 variables across 5 bowel segments. Higher scores indicate more severe disease. Percentage of participants achieving endoscopic remission based on SES-CD at either Week 26 or Week 52 will be reported in this outcome measure. | At Weeks 26 and 52 |
| Percentage of Participants in Endoscopic Remission at Both Week 26 and Week 52 | Endoscopic remission as per SES-CD is defined as SES-CD score from 0-2. SES-CD evaluates 4 endoscopic variables (ulcer size, percentage of surface area (SA) that is ulcerated, percentage of SA affected, and presence and type of narrowings in 5 colonic segments evaluated during ileocolonoscopy. Each variable is coded from 0 to 3 based on severity, where 0 is none or not severe and 3 is most severe case, with sum of scores for each variable ranging from 0 to 15, except for presence of narrowing. Presence of narrowing ranges from 0 to 11 since a severity of 3 represents a narrowing which a colonoscope cannot be passed and, thus, can only be observed once among the bowel segments. The overall SES-CD score ranges from 0 to 56 and is sum of 4 variables across 5 bowel segments. Higher scores indicate more severe disease. Percentage of participants achieving endoscopic remission based on SES-CD at both Weeks 26 and 52 will be reported in this outcome measure. | At Weeks 26 and 52 |
| Percentage of Participants in Deep Remission Based on the CDAI and SES-CD at Week 26 and Week 52 | Deep remission:CDAI <150 points and SES-CD 0-2. CDAI assesses CD per clinical signs such as number of liquid/soft stools,abdominal pain,general wellbeing,extra-intestinal manifestations of CD, antidiarrheal use,presence of abdominal mass, hematocrit and body weight. It has 8 factors each summed after adjustment with weighting factor; total score:0 to 600 points, higher scores=more severity. SES-CD evaluates 4 endoscopic variables(ulcer size, percentage of ulcerated surface area, percentage of affected surface area, and presence and type of narrowings in 5 colonic segments evaluated during ileocolonoscopy. Each variable is coded from 0=none or not severe to 3=most severe case; sum of the scores range from 0 to 15, except for narrowing. Presence of narrowing ranges from 0 to 11. Overall SES-CD score ranges from 0 to 56 and is the sum of 4 variables. Higher scores=more severe disease. Participants achieving deep remission at either Week 26 or 52 will be assessed in this outcome measure. | At Weeks 26 and 52 |
| Percentage of Participants in Deep Remission at Both Week 26 and Week 52 | Deep remission: CDAI <150 points and SES-CD 0-2. CDAI assesses CD per clinical signs such as number of liquid/soft stools,abdominal pain,general wellbeing,extra-intestinal manifestations of CD, antidiarrheal use,presence of abdominal mass, hematocrit and body weight. It has 8 factors each summed after adjustment with weighting factor; total score:0 to 600 points, higher scores=more severity. SES-CD evaluates 4 endoscopic variables(ulcer size, percentage of ulcerated surface area, percentage of affected surface area, and presence and type of narrowings in 5 colonic segments evaluated during ileocolonoscopy. Each variable is coded from 0=none or not severe to 3=most severe case; sum of the scores range from 0 to 15, except for narrowing. Presence of narrowing ranges from 0 to 11. Overall SES-CD score ranges from 0 to 56 and is the sum of 4 variables. Higher scores=more severe disease. Participants achieving deep remission at both Weeks 26 and 52 will be assessed in this outcome measure. | At Weeks 26 and Week 52 |
| Percentage of Participants With a Clinical Response (>=100-point Decrease from Baseline in CDAI Score) | Clinical response is defined as >=100-point decrease from Baseline in CDAI score. CDAI assesses CD based on clinical signs such as number of liquid or very soft stools, abdominal pain, general wellbeing, extra-intestinal manifestations of CD, antidiarrheal use, presence of abdominal mass, hematocrit and body weight. CDAI consist of eight factors, each summed after adjustment with a weighting factor. Total score ranges from 0 to 600 points. Higher scores indicate more severity. | At Weeks 12, 26, and 52 |
| Percentage of Participants With Complete Endoscopic Healing | Complete endoscopic healing is defined as SES-CD score ≤4 with a ≥2-point decrease from baseline and no individual subscore >1. SES-CD evaluates 4 endoscopic variables (ulcer size, percentage of the surface area that is ulcerated, percentage of the surface area affected, and presence and type of narrowings in 5 colonic segments evaluated during ileocolonoscopy (ileum, right colon, transverse colon, left colon, and rectum). Each variable is coded from 0 to 3 based on severity, where 0 is none or not severe and 3 is the most severe case, with the sum of the scores for each variable ranging from 0 to 15, except for presence of narrowing. Presence of narrowing ranges from 0 to 11 since a severity of 3 represents a narrowing which a colonoscope cannot be passed and, thus, can only be observed once among the bowel segments. The overall SES-CD score ranges from 0 to 56 and is the sum of 4 variables across 5 bowel segments. Higher scores indicate more severe disease. | At Weeks 26 and 52 |
| Percentage of Participants Using Oral Corticosteroids at Baseline who are in Clinical Remission Based on CDAI Score and had Discontinued Corticosteroids | Percentage of participants using oral corticosteroids at Baseline who are in clinical remission based on the CDAI score and had discontinued corticosteroids within >=30 days of Week 26 and within >= 90 days of Week 52. Clinical remission is defined as a CDAI score of ≤150 points. CDAI assesses CD based on clinical signs such as number of liquid or very soft stools, abdominal pain, general wellbeing, extra-intestinal manifestations of CD, antidiarrheal use, presence of abdominal mass, hematocrit and body weight. CDAI consist of eight factors, each summed after adjustment with a weighting factor. Total score ranges from 0 to 600 points. Higher scores indicate more severity. | From Week 26 to Week 52 |
| Change in SES-CD from Baseline to Week 26 and Week 52 | SES-CD evaluates 4 endoscopic variables (ulcer size, percentage of the surface area that is ulcerated, percentage of the surface area affected, and presence and type of narrowings in 5 colonic segments evaluated during ileocolonoscopy (ileum, right colon, transverse colon, left colon, and rectum). Each variable is coded from 0 to 3 based on severity, where 0 is none or not severe and 3 is the most severe case, with the sum of the scores for each variable ranging from 0 to 15, except for presence of narrowing. Presence of narrowing ranges from 0 to 11 since a severity of 3 represents a narrowing which a colonoscope cannot be passed and, thus, can only be observed once among the bowel segments. The overall SES-CD score ranges from 0 to 56 and is the sum of 4 variables across 5 bowel segments. Higher scores indicate more severe disease. | Baseline, Week 26 and Week 52 |
| Percentage of Participants with First CD Exacerbation After 26 Weeks | CD exacerbation is defined as a >70-point increase in CDAI from the prior visit on 2 occasions separated by a 2-week interval, and either CRP above normal or fecal calprotectin [FCP] >250 micrograms per gram (μg/g). CDAI assesses CD based on clinical signs such as number of liquid or very soft stools, abdominal pain, general wellbeing, extra-intestinal manifestations of CD, antidiarrheal use, presence of abdominal mass, hematocrit and body weight. CDAI consist of eight factors, each summed after adjustment with a weighting factor. Total score ranges from 0 to 600 points. Higher scores indicate more severity. | From Week 26 through Week 52 |
| Change in FCP Concentrations from Baseline to Week 12, Week 26, Week 42, and Week 52 | Baseline, Weeks 12, 26, 42, and 52 |
| GI Alliance Sun City | Recruiting | Sun City | Arizona | 85351 | United States |
|
| University of California San Diego Health (UCSD) | Recruiting | La Jolla | California | 92037 | United States |
|
| Cedars-Sinai Medical Center | Recruiting | Los Angeles | California | 90048 | United States |
|
| Hoag Hospital Newport Beach | Recruiting | Newport Beach | California | 92663 | United States |
|
| Medical Research Center of Connecticut, LLC | Recruiting | Hamden | Connecticut | 06518 | United States |
|
| Clinical Research of Osceola | Active, not recruiting | Kissimmee | Florida | 34741 | United States |
| Endoscopic Research Inc | Recruiting | Orlando | Florida | 32803 | United States |
|
| Alliance Clinical Research of Tampa, LLC | Recruiting | Tampa | Florida | 33615 | United States |
|
| Gastroenterology Consultants, P.C. | Recruiting | Roswell | Georgia | 30076 | United States |
|
| University of Chicago Medicine | Recruiting | Chicago | Illinois | 60637 | United States |
|
| GI Alliance - Illinois Gastroenterology Group - Glenview | Recruiting | Glenview | Illinois | 60026 | United States |
|
| GI Alliance - Illinois Gastroenterology Group LLC - Gurnee | Recruiting | Gurnee | Illinois | 60031 | United States |
|
| University of Kansas Medical Center | Recruiting | Kansas City | Kansas | 66160 | United States |
|
| Cotton ONeil Clinical Research Center | Recruiting | Topeka | Kansas | 66606 | United States |
|
| University of Louisville | Recruiting | Louisville | Kentucky | 40202 | United States |
|
| GI Alliance | Recruiting | Metairie | Louisiana | 70006 | United States |
|
| Tulane University | Recruiting | New Orleans | Louisiana | 70112 | United States |
|
| Huron Gastroenterology Associates, P.C. | Recruiting | Ypsilanti | Michigan | 48197 | United States |
|
| Mid-America Gastro-Intestinal Consultants | Recruiting | Kansas City | Missouri | 64111 | United States |
|
| BVL Clinical Research | Recruiting | Liberty | Missouri | 64068 | United States |
|
| Washington University School of Medicine | Recruiting | St Louis | Missouri | 63110 | United States |
|
| NYU Langone Health | Recruiting | New York | New York | 10016 | United States |
|
| University of Cincinnati | Recruiting | Cincinnati | Ohio | 45627 | United States |
|
| Ohio Gastroenterology group, Inc. | Recruiting | Columbus | Ohio | 43202 | United States |
|
| Great Lakes Gastroenterology Research, LLC | Recruiting | Mentor | Ohio | 44060 | United States |
|
| Gastro Intestinal Research Institute of Northern Ohio, LLC. | Recruiting | Westlake | Ohio | 44145 | United States |
|
| Digestive Disease Specialists, Inc. | Recruiting | Oklahoma City | Oklahoma | 73114 | United States |
|
| Allegheny Health Network | Recruiting | Wexford | Pennsylvania | 15090 | United States |
|
| University Gastroenterology | Recruiting | Providence | Rhode Island | 02094 | United States |
|
| Sanford Health Research | Recruiting | Rapid City | South Dakota | 57701 | United States |
|
| Texas Digestive Disease Consultants Cedar Park | Recruiting | Cedar Park | Texas | 78613 | United States |
|
| GI Alliance - Digestive Health Associates of Texas | Recruiting | Dallas | Texas | 75044 | United States |
|
| The University of Texas Health Science Center at Houston | Recruiting | Houston | Texas | 77030 | United States |
|
| Texas Digestive Disease Consultants Lubbock | Recruiting | Lubbock | Texas | 79410 | United States |
|
| GI Alliance - Mansfield | Recruiting | Mansfield | Texas | 76063 | United States |
|
| Gastroenterology Research of San Antonio, LLC | Recruiting | San Antonio | Texas | 78229 | United States |
|
| Southern Star Research Institute, LLC. | Recruiting | San Antonio | Texas | 78229 | United States |
|
| Texas Digestive Disease Consultants (TDDC), Southlake | Recruiting | Southlake | Texas | 76092 | United States |
|
| Tyler Research Institute, LLC | Recruiting | Tyler | Texas | 75701 | United States |
|
| GI Alliance - Webster | Recruiting | Webster | Texas | 77598 | United States |
|
| University of Utah Health | Recruiting | Salt Lake City | Utah | 84108 | United States |
|
| Washington Gastroenterology- GIA | Withdrawn | Bellevue | Washington | 98004 | United States |
| Washington Gastroenterology- GIA | Recruiting | Tacoma | Washington | 98405 | United States |
|
| Covenant Health | Recruiting | Edmonton | Alberta | T5K 2K4 | Canada |
|
| London Health Sciences Centre | Recruiting | London | Ontario | N6A 5A5 | Canada |
|
| West GTA Endoscopy Inc. | Withdrawn | Mississauga | Ontario | L5M 7N4 | Canada |
| Viable Clinical Research - North Bay | Recruiting | North Bay | Ontario | P1B 2H3 | Canada |
|
| Toronto Immune and Digestive Health Institute Inc. (TIDHI) | Recruiting | North York | Ontario | M6A3B4 | Canada |
|
| ABP Research Services Corp. | Recruiting | Oakville | Ontario | L6L 5L7 | Canada |
|
| Taunton Surgical Centre | Withdrawn | Oshawa | Ontario | L1J 0C7 | Canada |
| Toronto Digestive Disease Associates (TDDA) Inc. | Recruiting | Vaughan | Ontario | L4L 4Y7 | Canada |
|
| The Research Institute of the McGill University Health Centre | Recruiting | Montreal | Quebec | H3G 1A4 | Canada |
|
| ID | Term |
|---|---|
| D003424 | Crohn Disease |
| ID | Term |
|---|---|
| D015212 | Inflammatory Bowel Diseases |
| D005759 | Gastroenteritis |
| D005767 | Gastrointestinal Diseases |
| D004066 | Digestive System Diseases |
| D007410 | Intestinal Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C543529 | vedolizumab |
| D000068879 | Adalimumab |
| D000069549 | Ustekinumab |
| ID | Term |
|---|---|
| D061067 | Antibodies, Monoclonal, Humanized |
| D000911 | Antibodies, Monoclonal |
| D000906 | Antibodies |
| D007136 | Immunoglobulins |
| D007162 | Immunoproteins |
| D001798 | Blood Proteins |
| D011506 | Proteins |
| D000602 | Amino Acids, Peptides, and Proteins |
| D012712 | Serum Globulins |
| D005916 | Globulins |
Not provided
Not provided